Patterns of Failure after PACIFIC: How to Address Disease Recurrence after Chemoradiotherapy and Immunotherapy
Cole M. Friedes, MD+more
Dr. Cole M. Friedes and colleagues analyzed progression patterns in patients after receiving the PACIFIC regimen and showed that many patients are candidates for further ablative treatments. Read more
Research Supports Use of Lung Nodule Programs to Improve Early Detection Efforts
Erin JungmeyerA study by Dr. Raymond U. Osarogiagbon and colleagues found that such programs may benefit patients deemed too young or too old for lung cancer screening based on existing guidelines. Read more
US FDA Announces Multiple Moves with Implications for Lung Cancer Care
Erin JungmeyerAt the end of 2023, the agency approved repotrectinib for ROS1+ NSCLC, granted priority review for tarlatamab for advanced SCLC, and asked for an additional confirmatory trial for sotorasib for KRAS G12C-mutated NSCLC. Read more
As the IASLC celebrates its 50th year, the association’s journal moves to online only and the American Cancer Society recommends expanding screening eligibility. Read more
Modified Lung Cancer Screening Eligibility Requirements May Reduce Racial Disparities in Lung Cancer Screening, Treatment
Erin JungmeyerAccording to research presented during the North America Conference on Lung Cancer, moving away from pack-years of smoking history to duration of smoking history would increase the number of Black patients who qualify for screening to a rate comparable to that of white patients. Read more
Mesothelioma Patients Experienced Higher Levels of Toxicity on CheckMate743 Regimen Than Reported in Clinical Trials
Erin JungmeyerDr. Ned McNamee said the RIOMeso study is the first detailed report of real-world outcomes in Australian patients undergoing ipi + nivo treatment for pleural meso. Read more
IASLC Announces Partnerships to Spur Oncogene-Driven Lung Cancer Research, Address Global Challenges in Conquering Thoracic Cancers
Erin JungmeyerThe initiatives include a $2.5 million, 4-year research grant and projects to improve lung cancer biomarker testing uptake around the world. Read more
Patient Advocacy in 2023: A Look Back at Advocacy Efforts, Patient Concerns
Angus Pratt, MBAPatient research advocate Angus Pratt reflects on the past year of advocacy coverage in ILCN and how the movement has evolved in recent years. Read more
Proposed Criteria for Tumor Invasion Align with Clinical Factors, Offer Better Predictability, Study Finds
Erin JungmeyerResearchers evaluating the clinical significance of IASLC-proposed criteria found the recommendations better align with clinicopathologic risk factors and improve prognostication. Read more
The association recommends collecting data on tobacco use status to advance knowledge on the impacts of tobacco smoke in the context of cancer clinical trials. Read more